See how leading pharma teams build early pricing strategy with evidence, not assumption
Book a live GPI Horizon demo and discover how your team can generate a structured, market-specific view of value and pricing potential — in hours rather than weeks.
Instant self-service outputs — generate a price corridor and value forecast almost instantaneously
Retrospectively backtested — validated against actual achieved prices, presented at ISPOR with full source transparency
Trusted by Top 10 global pharma and emerging biotech across rare disease and oncology
Complete libraries of value-scored data — ready-to-use scored comparable data for rare disease and oncology assets across EU5 & US
No lengthy onboarding — no commitment required for an initial demo
Book your demo
Choose how you'd like to connect
Pick a time in the calendar, or if nothing suits, leave your details and we'll arrange something that works.
Book a time
Pick a slot that works for you
Select a time below to speak with a GPI specialist. We'll tailor the walkthrough to your therapy area and markets of interest.
No commitment required — 30–45 minutes, tailored to your therapy area. Most teams book 2–3 weeks out, so the sooner you reach out the better.
Send a message
Can't find a suitable time?
Leave your details below and a member of our team will be in touch to arrange a time that works for you.
Trusted by leading pharmaceutical companies worldwide
What you'll see in your demo
A structured, evidence-based starting point — before payer research begins
GPI Horizon uses payer-validated value frameworks and analogue benchmarking to generate evidence-based price forecasts — without requiring primary payer research or direct market comparators. Competitors may offer attractive platforms, but very few hold the depth of value-scored comparable data that GPI Horizon provides. Here's what the demo covers.
Analogue identification
See how GPI Horizon identifies the most relevant analogues for your asset — not by matching indication, but by comparing patient population size, disease severity profile, and clinical endpoint similarity. The approach that works even when no direct comparator exists.
Payer-validated value scoring
See how GPI Horizon scores your asset across four domains — burden & unmet need, product characteristics, trial design, and clinical benefit — using weightings derived from real HTA assessments by G-BA, HAS, NICE, and other major payer bodies. Each market weights these factors differently, and Horizon reflects that.
Evidence-based price corridor
Once your asset is scored, GPI Horizon identifies analogues with a similar value profile and uses their actual achieved prices to forecast your corridor. Not estimates — forecasts derived from real-world pricing outcomes, delivered in hours rather than months.
Strategic scenario planning
Explore how GPI Horizon answers the three questions that matter before Phase 2/3 commitment: Will I be reimbursed? What price can I achieve? Which markets should I prioritise? Run scenarios across clinical endpoints, market sequencing, and evidence assumptions in moments.
Board-ready, traceable outputs
Every value score and price forecast is traceable back to its source data. Excel exports cover underlying inputs, analogue rationale, HTA assessment references, and reimbursement timelines — giving you the methodology to defend your numbers to boards, investors, and deal partners.
Optional expert validation
When you need to go beyond the platform output, GPI's specialist team can validate your GPI Horizon findings against primary payer research — typically within two to four weeks. Used by teams preparing Phase 3 investment cases, licensing decisions, and market access submissions.
BacktestedRetrospectively validated against actual achieved prices
InstantSelf-service output generation via the platform
2–4 wksTo optional external payer validation if required
Scored librariesComplete value-scored data libraries for rare disease & oncology
GPI is always ready to listen, flexible, available and amenable to all business needs. Pfizer relies heavily on GPI's cost of treatment calculations in order to determine which products we have to report on, and therefore upholding our reputation.
Michelle PardoPricing Manager, Pfizer Inc.
Frequently asked questions
Questions about GPI Horizon or your demo
Everything you need to know before your call.
What is GPI Horizon?
+
GPI Horizon is GPI's self-service early pricing and value strategy platform. It combines multi-criteria decision analysis with forecasting to generate evidence-based price corridors and value assessments for pharmaceutical assets — typically in hours rather than weeks. It's designed to give teams a structured, objective starting point before engaging in costly payer research, backed by complete libraries of value-scored comparable data for rare disease and oncology assets across the EU5 and US.
Who is a GPI Horizon demo suitable for?
+
GPI Horizon is used by Heads of Market Access, Pricing Directors, Portfolio and Commercial Strategy Leads, and Evidence Planning teams — most commonly at top 10 global pharmaceutical companies and small to mid-size biotech firms during early development and early pricing stages. If you're involved in setting pricing corridors, prioritising assets, or planning evidence generation, this demo is for you.
How long does a GPI Horizon demo take?
+
A live GPI Horizon demo typically runs for 30 to 45 minutes. We'll cover the platform setup, comparator or analogue selection, asset scoring, and output review including price corridor analysis. We're happy to tailor the focus to your specific therapy area or market of interest.
Is GPI Horizon relevant before we have clinical data?
+
Yes — that's precisely where GPI Horizon adds the most value. It's designed for early development, before a full clinical dataset exists. You score your asset based on the profile you expect to achieve, and you can run multiple scenarios to test the impact of different outcomes. This helps align internal assumptions and informs evidence planning early.
What markets does GPI Horizon cover?
+
GPI Horizon is strongest in the EU5 (Germany, France, Italy, Spain, and the UK) and the United States. It has additional coverage across APAC, the GCC, and the Nordics. It was originally built for rare diseases and has since been validated for oncology through extensive payer research — with complete libraries of value-scored data for orphan-designated assets across the EU5 and US.
